Last Updated: August 26, 2026

Details for Patent: 8,946,292

Name: Drug Patent Intelligence for US Patent 8946292
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,946,292 protect, and when does it expire?

Patent 8,946,292 protects DYLOJECT and is included in one NDA.

This patent has twenty-four patent family members in eleven countries.

Summary for Patent: 8,946,292

Title:	Formulations of low dose diclofenac and beta-cyclodextrin
Abstract:	The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 75 mg, e.g., from about 18.75 mg to about 37.5 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention.
Inventor(s):	Curtis Wright, Daniel B. Carr, Fred H. Mermelstein
Assignee:	Javelin Pharmaceuticals Inc
Application Number:	US13/106,697
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,946,292
Patent Claim Types: see list of patent claims	Use; Composition; Delivery;

Drugs Protected by US Patent 8,946,292

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Javelin Pharms Inc	DYLOJECT	diclofenac sodium	SOLUTION;INTRAVENOUS	022396-001	Dec 23, 2014		DISCN	Yes	No	8,946,292	⤷ Start Trial				MANAGEMENT OF PAIN	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,946,292

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007230716	⤷ Start Trial
Brazil	PI0709409	⤷ Start Trial
Canada	2647348	⤷ Start Trial
China	101410123	⤷ Start Trial
China	102846585	⤷ Start Trial
European Patent Office	2004203	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.